29th week of 2019 patent applcation highlights part 23 |
Patent application number | Title | Published |
20190218207 | 3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NAMPT Modulators | 2019-07-18 |
20190218208 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | 2019-07-18 |
20190218209 | CRYSTAL FORMS OF NBI-98854, PREPARATION METHOD AND USE THEREOF | 2019-07-18 |
20190218210 | CRYSTAL FORM OF PYRROLOQUINOLINE QUINONE SODIUM SALT AND PREPARATION METHOD AND USE THEREOF | 2019-07-18 |
20190218211 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | 2019-07-18 |
20190218212 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | 2019-07-18 |
20190218213 | FUSED PYRIMIDINE PIPERIDINE CYCLIC DERIVATIVE, PREPARATION PROCESS AND USE THEREOF | 2019-07-18 |
20190218214 | Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof | 2019-07-18 |
20190218215 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | 2019-07-18 |
20190218216 | PYRIDOPYRIMIDINES DERIVATIVES COMPOUNDS | 2019-07-18 |
20190218217 | Tetrahydro-Pyrido-Pyrimidine Derivatives as PI3Kdelta inhibitors | 2019-07-18 |
20190218218 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | 2019-07-18 |
20190218219 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | 2019-07-18 |
20190218220 | HETEROARYL COMPOUNDS AND USES THEREOF | 2019-07-18 |
20190218221 | COMPOSITIONS FOR ACTIVATING PYRUVATE KINASE | 2019-07-18 |
20190218222 | PROCESS FOR THE PREPARATION OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIM- IDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE AND SALTS THEREOF | 2019-07-18 |
20190218223 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | 2019-07-18 |
20190218224 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | 2019-07-18 |
20190218225 | NOVEL CHIRAL SYNTHESIS OF N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-A]- PYRAZINES | 2019-07-18 |
20190218226 | PRODRUGS OF ANTICANCER AGENTS INDOTECAN AND INDIMITECAN | 2019-07-18 |
20190218227 | SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS | 2019-07-18 |
20190218228 | ANTI-CANCER AGENTS AND PREPARATION THEREOF | 2019-07-18 |
20190218229 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | 2019-07-18 |
20190218230 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | 2019-07-18 |
20190218231 | Crystal Forms And Salt Forms Of 7h-Pyrrolo[2,3-D]Pyrimidine Compounds And Preparation Method Thereof | 2019-07-18 |
20190218232 | Preparation Of Aromatic-Substituted Silylamines By The Dehydrogenative Coupling Of Aromatic-Substituted Amine N-H And Si-H Bonds | 2019-07-18 |
20190218233 | GROUP 4 TRANSITION METAL-CONTAINING FILM FORMING COMPOSITIONS FOR VAPOR DEPOSITION OF GROUP 4 TRANSITION METAL-CONTAINING FILMS | 2019-07-18 |
20190218234 | PROCESS FOR THE PURIFICATION OF L-ALPHA-GLYCEROPHOSPHORYLCHOLINE | 2019-07-18 |
20190218235 | Phthalonitrile Monomer Modified with Organophosphorus Fragments, a Method of Producing thereof, a Binder Based Thereon, and a Prepreg | 2019-07-18 |
20190218236 | SYNTHESIS OF BACKBONE MODIFIED MORPHOLINO OLIGONUCLEOTIDES AND CHIMERAS USING PHOSPHORAMIDITE CHEMISTRY | 2019-07-18 |
20190218237 | ORGANIC PHOSPHORUS-BASED COMPOUND, AND FLAME RETARDANT AND FLAME-RETARDANT PRODUCT COMPRISING THE SAME | 2019-07-18 |
20190218238 | AMINOIODOSILANES AND METHODS OF SYNTHESIZING THESE AMINOIODOSILANES | 2019-07-18 |
20190218239 | DEHYDROGENATION OF NEAT FORMIC ACID | 2019-07-18 |
20190218240 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND, AND ORGANIC LIGHT-EMITTING APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | 2019-07-18 |
20190218241 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF CANCERS | 2019-07-18 |
20190218242 | METHOD OF COALESCING A SUBSTANCE | 2019-07-18 |
20190218243 | IMPROVED PROCESSES FOR THE PREPARATION OF SOFOSBUVIR AND INTERMEDIATES THEREOF | 2019-07-18 |
20190218244 | ANTISENSE NUCLEIC ACIDS | 2019-07-18 |
20190218245 | COMPOUNDS AND METHODS INVOLVING STEROLS | 2019-07-18 |
20190218246 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | 2019-07-18 |
20190218247 | METHODS AND SYSTEMS FOR PROTEIN REFOLDING | 2019-07-18 |
20190218248 | METHODS OF PURIFYING PROTEINS | 2019-07-18 |
20190218249 | A PROCESS FOR PURIFICATION OF CARFILZOMIB INTERMEDIATE | 2019-07-18 |
20190218250 | METHODS OF REDUCING LEVEL OF ONE OR MORE IMPURITIES IN A SAMPLE DURING PROTEIN PURIFICATION | 2019-07-18 |
20190218251 | DEUTERATED COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCERS ASSOCIATED WITH ETBR ACTIVATION | 2019-07-18 |
20190218252 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling | 2019-07-18 |
20190218253 | Therapeutic SALL4 Peptide | 2019-07-18 |
20190218254 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC | 2019-07-18 |
20190218255 | SCN9A ANTISENSE OLIGONUCLEOTIDES | 2019-07-18 |
20190218256 | MUTANT LIGHT-INDUCIBLE ION CHANNEL OF CHANNELRHODOPSIN | 2019-07-18 |
20190218257 | NOVEL NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | 2019-07-18 |
20190218258 | Compositions And Related Methods For Modulating Alkaloid Production By Controlling PMT Promoter Activation Mediated By Transcriptional Factors ERF and MYC | 2019-07-18 |
20190218259 | COMPOSITIONS AND METHODS FOR BROWN FAT INDUCTION AND ACTIVITY USING FNDC5 | 2019-07-18 |
20190218260 | COMPOSITIONS AND METHODS FOR ENHANCING IMMUNOGENIC CROSS-PRESENTATION OF TUMOR ANTIGENS | 2019-07-18 |
20190218261 | TARGETED ENHANCED DNA DEMETHYLATION | 2019-07-18 |
20190218262 | TWISTED GASTRULATION POLYPEPTIDES AND USES THEREOF | 2019-07-18 |
20190218263 | NORRIN REGULATION OF CELLULAR PRODUCTION OF JUNCTION PROTEINS AND USE TO TREAT RETINAL VASCULATURE EDEMA | 2019-07-18 |
20190218264 | TARGETED EFFECTOR PROTEINS AND USES THEREOF | 2019-07-18 |
20190218265 | Novel Ligand and Use Thereof | 2019-07-18 |
20190218266 | FUSION PROTEIN COMPRISING ANTIFREEZE PROTEIN AND HUMAN EPIDERMAL GROWTH FACTOR WITH INCREASED ANTI-OXIDANT ACTIVITY AND SKIN CELL PROLIFERATION EFFECT AND COSMETIC COMPOSITION FOR ANTI-WRINKLE COMPRISING THE SAME AS EFFECTIVE COMPONENT | 2019-07-18 |
20190218267 | IL-21 (HETERODIMERIC FC-FUSED IL-21) FUSED TO IMMUNOGLOBULIN HEAVY CHAIN CONSTANT REGION HETERODIMER (HETERODIMERIC FC), AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 2019-07-18 |
20190218268 | AQUEOUSLY SOLUBLE & CHEMICALLY STABLE GLUCAGON PEPTIDES | 2019-07-18 |
20190218269 | TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | 2019-07-18 |
20190218270 | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS | 2019-07-18 |
20190218271 | MUTANT LIGHT-INDUCIBLE ION CHANNEL OF CHRIMSON | 2019-07-18 |
20190218272 | ALK4:ACTRIIB HETEROMULTIMERS AND USES THEREOF | 2019-07-18 |
20190218273 | ANGIOPOIETIN-2 SPECIFIC TIE2 RECEPTOR | 2019-07-18 |
20190218274 | ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE | 2019-07-18 |
20190218275 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS | 2019-07-18 |
20190218276 | METHODS FOR DETERMINING SPATIAL AND TEMPORAL GENE EXPRESSION DYNAMICS IN SINGLE CELLS | 2019-07-18 |
20190218277 | ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND METHODS OF USE | 2019-07-18 |
20190218278 | A METHOD FOR TREATING AGE-RELATED MACULAR DEGENERATION IN A PATIENT | 2019-07-18 |
20190218279 | PAC1 ANTIBODIES AND USES THEREOF | 2019-07-18 |
20190218280 | Compositions and Methods for Treating Cancer with Anti-Mesothelin Immunotherapy | 2019-07-18 |
20190218281 | TREATMENT OF TAUOPATHIES | 2019-07-18 |
20190218282 | NOVEL ANTIBODY FORMAT | 2019-07-18 |
20190218283 | METHODS FOR INHIBITING MYOSTATIN ACTIVATION BY ADMINISTERING ANTI-PRO/LATENT MYOSTATIN ANTIBODIES | 2019-07-18 |
20190218284 | METHODS OF TREATING EOSINOPHILIC GASTROINTESTINAL DISEASES | 2019-07-18 |
20190218285 | Long-Acting Therapeutic Fusion Proteins | 2019-07-18 |
20190218286 | COMPOSITIONS AND METHODS FOR MEASURING NMU AND FOR TREATMENT USING ANTI-NMU AGENTS | 2019-07-18 |
20190218287 | TRPM4 CHANNEL INHIBITORS FOR STROKE TREATMENT | 2019-07-18 |
20190218288 | FcgammaRIIB-Specific Antibodies and Methods of Use Thereof | 2019-07-18 |
20190218289 | METHODS FOR ACHIEVING THERAPEUTICALLY EFFECTIVE DOSES OF ANTI-CD47 AGENTS | 2019-07-18 |
20190218290 | CAMEL DERIVED POLYPEPTIDES BINDING HUMAN CD3, IDENTIFIED USING A NOVEL ONE-STEP METHOD | 2019-07-18 |
20190218291 | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | 2019-07-18 |
20190218292 | ANTIBODY FOR CANCER TREATMENT | 2019-07-18 |
20190218293 | USE OF AN ANTI-PD-1 ANTIBODY IN COMBINATION WITH AN ANTI-CD30 ANTIBODY IN CANCER TREATMENT | 2019-07-18 |
20190218294 | USE OF AN ANTI-PD-1 ANTIBODY IN COMBINATION WITH AN ANTI-MESOTHELIN ANTIBODY IN CANCER TREATMENT | 2019-07-18 |
20190218295 | ANTI-PD-1 ANTIBODIES | 2019-07-18 |
20190218296 | ANTI-PD-L1 ANTIBODIES AND METHODS OF USE | 2019-07-18 |
20190218297 | METHODS OF CANCER TREATMENT AND THERAPY USING A COMBINATION OF ANITBODIES THAT BIND GLYCOSYLATED PD-L1 | 2019-07-18 |
20190218298 | NEUTRALIZING ANTIBODIES TO THE ALPHA V BETA 8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY | 2019-07-18 |
20190218299 | Methods for Treating Disorders Associated with Fibrosis and Systemic Sclerosis | 2019-07-18 |
20190218300 | LIQUID PHARMACEUTICAL COMPOSITION | 2019-07-18 |
20190218301 | METHODS OF TREATING SEVERE INSULIN RESISTANCE BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING | 2019-07-18 |
20190218302 | ANTI-CANCER COMBINATION TREATMENT | 2019-07-18 |
20190218303 | CD37-Binding Molecules and Immunoconjugates Thereof | 2019-07-18 |
20190218304 | POTENTIATING THE EFFECT OF ATP RELEASE | 2019-07-18 |
20190218305 | OPTIMIZING THE PRODUCTION OF ANTIBODIES | 2019-07-18 |
20190218306 | METHOD OF INHIBITING ECTOPIC CALCIFICATION | 2019-07-18 |